Sugi Predict

Sugi Predict / Compounds / SCHEMBL770738

SCHEMBL770738

SCHEMBL770738

CC(N)C(=O)OC1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 2/20 0.50
▸ EPHX1 P07099 2/20 0.44
▸ NAAA Q02083 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ CYP2C19 P33261 2/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ GAA P10253 1/20 0.36
▸ FABP7 O15540 1/20 0.36
▸ FABP5 Q01469 1/20 0.36
▸ CYP3A4 P08684 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ STS P08842 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38556 1.00 CYP19A1 (0.50) CYP19A1EPHX1NAAAL3MBTL1HTT
SCHEMBL16554168 1.00 CYP19A1 (0.50) CYP19A1EPHX1NAAAL3MBTL1HTT
SCHEMBL16373577 1.00 CYP19A1 (0.50) CYP19A1EPHX1NAAAL3MBTL1HTT
SCHEMBL8131133 1.00 CYP19A1 (0.50) CYP19A1EPHX1NAAAL3MBTL1HTT
SCHEMBL18630281 1.00 CYP19A1 (0.50) CYP19A1EPHX1NAAAL3MBTL1HTT
SCHEMBL16554167 1.00 CYP19A1 (0.50) CYP19A1EPHX1NAAAL3MBTL1HTT
Hydrochloric Acid SCHEMBL28986488 0.98 CYP19A1 (0.49) CYP19A1EPHX1NAAAL3MBTL1HTT
Hydrochloric Acid SCHEMBL28854937 0.98 CYP19A1 (0.49) CYP19A1EPHX1NAAAL3MBTL1HTT
Hydrochloric Acid SCHEMBL28854935 0.98 CYP19A1 (0.49) CYP19A1EPHX1NAAAL3MBTL1HTT
Hydrochloric Acid SCHEMBL18492053 0.98 CYP19A1 (0.49) CYP19A1EPHX1NAAAL3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3013340-B9 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN PHARMACEUTICALS INC (US) 2023-10-04 — — EP claimed
EP-3013340-B1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN BIOPHARMA INC (US) 2023-06-07 — — EP claimed
US-20220048912-A1 CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS JANSSEN PHARMACEUTICA NV (BE) 2022-02-17 — — US claimed
US-20220033406-A1 CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS Janssen Pharmaceuticals, Inc. 2022-02-03 — — US claimed
EP-3912984-A1 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV Janssen BioPharma, Inc. (US) 2021-11-24 — — EP claimed
EP-3894395-A2 CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS Janssen BioPharma, Inc. (US) 2021-10-20 — — EP claimed
EP-3894394-A1 CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS Janssen BioPharma, Inc. (US) 2021-10-20 — — EP claimed
EP-2935303-B1 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV JANSSEN BIOPHARMA INC (US) 2021-02-17 — — EP claimed
US-RE48171-E1 Substituted nucleosides, nucleotides and analogs thereof Janssen Biopharma, Inc. (US) 2020-08-25 — — US claimed
WO-2020121122-A1 CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS Janssen Biopharma, Inc. (US) 2020-06-18 — — WO claimed
WO-2014100498-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2014-06-26 — — WO claimed
WO-2014100505-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2014-06-26 — — WO claimed
WO-2013142525-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2013-09-26 — — WO claimed
EP-2619216-A1 SUBSTITUTED NUCLEOTIDE ANALOGS Alios Biopharma, Inc. (US) 2013-07-31 — — EP claimed
WO-2013096680-A1 SUBSTITUTED PHOSPHOROTHIOATE NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2013-06-27 — — WO claimed
WO-2013096679-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2013-06-27 — — WO claimed
WO-2012040126-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-29 — — WO claimed
WO-2012040127-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-29 — — WO claimed
US-20120070411-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-22 — — US claimed
US-20120071434-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-22 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220033406-A1 CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS PNP, TYMP, HAVCR2 CYP19A1 1619/4885EPHX1 2015/4885NAAA 1828/4885
US-20120071434-A1 SUBSTITUTED NUCLEOTIDE ANALOGS PNP, NUDT1, TYMP CYP19A1 4058/4885EPHX1 1477/4885NAAA 527/4885
US-20120070411-A1 SUBSTITUTED NUCLEOTIDE ANALOGS PNP, NTPCR, NUDT1 CYP19A1 3345/4885EPHX1 1231/4885NAAA 114/4885
US-20220048912-A1 CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS TYMP, POLB, HMBS CYP19A1 1712/4885EPHX1 3023/4885NAAA 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.